抗葡萄糖类药物与阿尔茨海默病之间的关联
Chien-Chih Chou1,2,3,4, Yi-An Lu2, Chien-Hsiang Weng5,6
1School of Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
Eye (London, England)
|September 28, 2024
概括
长期使用局部α-2上腺激动剂可能会增加阿尔茨海默氏病 (AD) 风险在眼患者. 青光眼本身,在所有亚型中,与患AD的风险更高有关.
科学领域:
- 眼科医生 眼科 眼科
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 玻璃眼是导致不可逆转失明的主要原因.
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病.
- 青光眼药物和AD风险之间的关系尚未完全理解.
研究的目的:
- 为了研究长期使用局部玻璃眼药物与阿尔茨海默病 (AD) 风险之间的关联.
- 为了在不同青光眼亚型中比较AD风险.
- 评估与特定类型的青光眼药物相关的风险.
主要方法:
- 一项全国性基于人口的队列研究,使用台湾保险索赔数据 (2008-2019).
- 包括45岁以上的成年人,有或没有青光眼,不包括那些有先前存在的阿尔茨海默病.
- 分析90天以上的药物使用,包括α-2上腺激动剂,β-阻断剂和其他药物.
主要成果:
- 接受局部α-2上腺激素激动剂单疗法的大眼患者的AD风险较高 (aHR 1.15) 与β抑制剂相比.
- 与对照组相比,所有青光瘤亚型 (POAG,NTG,PACG,未指明) 都与AD风险显著增加有关.
- 对于POAG (aHR 1.23),NTG (aHR 1.49),PACG (aHR 1.35) 和未指定的玻璃眼 (aHR 1.36) 发现了特定的风险增加.
结论:
- 局部的α-2上腺激动剂可能会增加青光眼患者的AD风险,因此需要谨慎使用.
- 玻璃眼,无论亚型,似乎是发展阿尔茨海默病的独立风险因素.
- 需要进一步的研究来阐明青光眼-AD关联背后的机制.
相关概念视频
Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170
Alzheimer's Disease: Overview
451
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
451
Open Angle Glaucoma: Treatment
403
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
403
Glaucoma: Overview
527
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
527
Antiepileptic Drugs: Glutamate Antagonists
292
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
292
Angle Closure Glaucoma: Treatment
448
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
448


